stroke

[Nature Communications] The authors investigated if focal ablation of astrocytes were sufficient to disrupt the blood-brain barrier in mice. Targeted two-photon chemical apoptotic ablation of astrocytes induced a plasticity response whereby surrounding astrocytes extended processes to cover vascular vacancies.

[Florida State University News] The National Institutes of Health (NIH) is funding a $1.8 million project led by a researcher at the Florida A and M Univeristy-Florida State University College of Engineering that will use artificially grown, simplified mini-organs to create medicine that targets brain cells damaged by stroke.

[Athersys, Inc.] Athersys, Inc. announced that its partner, HEALIOS K.K. provided updates on its two clinical programs evaluating MultiStem® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.

[Journal of Clinical Investigation] The authors observed increased plasma and platelet surface expressed high mobility group box 1 in stroke patients. Mechanistically, platelets were identified as the critical source for HMGB1 causing neutrophil extracellular trap in the acute phase of stroke.

[Full Journal Title] Novo Nordisk announced that the FDA has approved a 2.0 mg dose of Ozempic® a glucagon-like peptide-1 analogue for the treatment of adults with type 2 diabetes.

[Scientific Reports] With the aim of designing a preclinical study evaluating an intracerebral cell-based therapy for stroke, an observational study was performed in the rat suture model of ischemic stroke.